AI assistant
Celyad Oncology SA — Share Issue/Capital Change 2017
Nov 24, 2017
3927_rns_2017-11-24_f0549b75-4aca-4e4f-9b3d-e92574686596.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)
Celyad SA (NYSE Euronext Brussels and NYSE Euronext Paris: CYAD), disclose the information required under article 15, § 1 of the Law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies.
Following the exercise of 5,866 warrants of the Company on 1 August 2017, the share capital is increased to 34,337,134.57 EUR and is represented by 9,867,844 shares.
FIGURES – MODIFIED ON 1 AUGUST 2017 FOLLOWING THE EXERCISE OF WARRANTS
New shares issued following the exercise of Company's warrants: 5,866.
Company's share capital: 33,151,900.63 EUR.
Total number of shares with voting rights: 9,867,844.
Total number of voting rights (= denominator): 9,867,844
Statutory thresholds – unchanged
Statutory thresholds for participation (article 12 of the by-laws): 5%, 10%, 15%, 20% and so by increments of 5%.
CONTACT PERSON FOR REGULATED INFORMATION (FINANCIAL, TRANSPARENCY)
According to Law, any transparency declaration must be sent to our Company by email to the attention of Patrick Jeanmart, Chief Financial Officer (CFO): [email protected].
Further questions about the content of this release can be sent to [email protected].
***END**